This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

6 candidates mapped to SDH-deficient disease pathways

All (27)established (4)clinical trial (4)preclinical (13)theoretical (6)
Olaparib

Lynparza

preclinical

PARP inhibitor (PARP1/2)

Sdh Driven HrdOxidative Stress Ros
Evidence Score
58
FDA Approved
Daporinad (FK866)

APO866

preclinical

NAMPT inhibitor (NAD⁺ biosynthesis inhibitor)

Nad MetabolismOxidative Stress Ros
Evidence Score
48
Metformin

Glucophage

preclinical

Biguanide / Complex I inhibitor / AMPK activator

Mtor Pi3k AktOxidative Stress Ros
Evidence Score
40
FDA Approved
Ascorbic Acid (High-dose IV)
preclinical

TET enzyme cofactor / α-KG-dependent dioxygenase activator

Epigenetic DysregulationOxidative Stress Ros
Evidence Score
38
DENSPM (N1,N11-Diethylnorspermine)
preclinical

Polyamine analogue / SSAT inducer

Polyamine MetabolismOxidative Stress Ros
Evidence Score
38
Dichloroacetate (DCA)
preclinical

Pyruvate dehydrogenase kinase inhibitor

Hif PseudohypoxiaOxidative Stress Ros
Evidence Score
35